CA2423358A1 - Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers - Google Patents
Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers Download PDFInfo
- Publication number
- CA2423358A1 CA2423358A1 CA002423358A CA2423358A CA2423358A1 CA 2423358 A1 CA2423358 A1 CA 2423358A1 CA 002423358 A CA002423358 A CA 002423358A CA 2423358 A CA2423358 A CA 2423358A CA 2423358 A1 CA2423358 A1 CA 2423358A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- residue
- amino acid
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/49—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
Abstract
The present invention provides compositions comprising at least one GHB moiety bonded to at least one physiologically compatible carrier molecule. The compositions can enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, or can target specific organs.
Claims (36)
1. A compound of the formula (I):
wherein Y is H or a hydroxyl-protecting group, X is the residue of a carbohydrate and n has a value of 1 to the number of available hydroxyl groups in said carbohydrate, or a pharmaceutically acceptable salt thereof.
wherein Y is H or a hydroxyl-protecting group, X is the residue of a carbohydrate and n has a value of 1 to the number of available hydroxyl groups in said carbohydrate, or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 wherein X is a saccharide.
3. The compound of claim 1 wherein Y is H, a (C4-C6)acetal, (C1-C5)acyl or (C1-C5)alkyl.
4. The compound of claim 1 wherein X is the residue of a monosaccharide or the residue of a disaccharide.
5. The compound of claim 1 wherein X is the residue of a polysaccharide.
6. The compound of claim 4 or 5 wherein the residue contains at least one CHOH-CHOH moiety that is protected as an acetal or ketal.
7. The compound of claim 1 wherein X is the residue of a chemically modified cellulose.
8. The compound of claim 7 wherein the chemically modified cellulose is hydroxypropyl-methylcellulose, hydroxyethylcellulose or hydroxypropylcellulose.
9. The compound of claim 1 wherein the carbohydrate is a chemically modified saccharide or a chemically modified starch.
10. A pharmaceutical composition comprising the compound of claim 1 in combination with a pharmaceutically acceptable carrier.
11. The composition of claim 10 which is adapted for oral administration.
12. The composition of claim 10 which is adapted for topical or local administration.
13. A compound of the formula (II):
(R'O(CH2)3CO2)m(ROC(O)(CH2)3OC(O))q-(X)-(Y)n-(Z)n-(CO2(CH2)3CO2R)p(O2C(CH)2)3OR~I) wherein R' is H or a hydroxyl-protecting group, R is H, (C1-C4)alkyl or benzyl, X and Z are each residues of a hydroxy group-containing amino acid or a bis(carboxy)amino acid, Y is a moiety covalently linking X and Z, n is 0-1, m and k are 0 to the number of available hydroxy groups on the amino acids X and Z; q and p are 0 to the number of available CO2 groups on amino acids X and Z, with the proviso that both m and q and both p and k are not zero, or a pharmaceutically acceptable salt thereof.
(R'O(CH2)3CO2)m(ROC(O)(CH2)3OC(O))q-(X)-(Y)n-(Z)n-(CO2(CH2)3CO2R)p(O2C(CH)2)3OR~I) wherein R' is H or a hydroxyl-protecting group, R is H, (C1-C4)alkyl or benzyl, X and Z are each residues of a hydroxy group-containing amino acid or a bis(carboxy)amino acid, Y is a moiety covalently linking X and Z, n is 0-1, m and k are 0 to the number of available hydroxy groups on the amino acids X and Z; q and p are 0 to the number of available CO2 groups on amino acids X and Z, with the proviso that both m and q and both p and k are not zero, or a pharmaceutically acceptable salt thereof.
14. A compound of the formula (III):
wherein R1 is H or a hydroxyl-protecting group, R is H, (C1-C4)alkyl or benzyl, X is a residue of a hydroxy group-containing amino acids, Z is the residue of a hydroxy group-containing amino acid or a bis(carboxy) group-containing amino acid, Y is a moiety covalently linking X and Z, n is 0-1, m is 1 to the number of available hydroxy groups in amino acid X, p is 1 to the number of available groups on the amino acid X or Z, or a pharmaceutically acceptable salt thereof.
wherein R1 is H or a hydroxyl-protecting group, R is H, (C1-C4)alkyl or benzyl, X is a residue of a hydroxy group-containing amino acids, Z is the residue of a hydroxy group-containing amino acid or a bis(carboxy) group-containing amino acid, Y is a moiety covalently linking X and Z, n is 0-1, m is 1 to the number of available hydroxy groups in amino acid X, p is 1 to the number of available groups on the amino acid X or Z, or a pharmaceutically acceptable salt thereof.
15. The compound of claim 13 wherein each of m, q, p and k is 1.
16. The compound of claim 13 wherein m and k are 0, and q and p are 1.
17. The compound of claim 13 wherein n = 0, m = 0 and k = 0 and X is glutamic acid, aspartic acid or tyrosine.
18. The compound of claim 14 wherein m=p=1, n is 0 and X is tyrosine, threonine, or serine.
19. The compound of claim 14 wherein m=n=p=1 and Y is C(O)CH2CH2C(O) or C(O)CH=CH(CO).
20. A compound of formula (IV):
wherein L and L' are individually H, (C1-C6)alkyl or a hydroxyl protecting group or an organic moiety comprising at least one fatty alcohol, fatty ester or analog thereof, wherein at least one of L and L' is said moiety.
wherein L and L' are individually H, (C1-C6)alkyl or a hydroxyl protecting group or an organic moiety comprising at least one fatty alcohol, fatty ester or analog thereof, wherein at least one of L and L' is said moiety.
21. The compound of claim 17 wherein at least one of L' or L is -(A)(Y)(Z)n, wherein A is (C1-C6)alkyl, Y is H, OH N(R1)(R2)(R3) or [-O(PO3-)-AN(R1)(R2)(R3), wherein R1, R2 and R3 are each (C1-C4)alkyl or R1 and R2 together with N are a (C5-C7)heterocyclic ring, optionally substituted with 1 or 2 N(R3), S, non-peroxide O or a combination thereof; n is 1-2 and Z is YR, wherein Y is O, S, NH, N(CH3), NHC(O) or OC(O) and R is (C8-C22)alkyl, optionally substituted with 1-2 double bonds, or a pharmaceutically acceptable salt thereof, with the proviso that when one of L or L' is 1,3-dihexadecanoylprop-2-yl, the other is not H.
22. The compound of claim 21 wherein L' is -(A)(Y)(Z)n and L is H, (C1-C6)alkyl or a hydroxyl protecting group.
23. The compound of claim 21 or 22 wherein Y is OC(O).
24. The compound of claim 20 wherein R is (C10-C22)alkyl.
25. The compound of claim 21 or 22 wherein Y is -O(PO3-)CH2CH2N(CH3)3+.
26. The compound of claim 21 or 22 wherein (A)(Y)(Z)n is -CH[CH2Z][CH2Y].
27. A compound of the formula (V):
wherein L is individually H, (C1-C6)alkyl or a hydroxyl protecting group, n is 6, and L" is (C2-C12)alkyl, optionally interrupted by 1-3-O-.
wherein L is individually H, (C1-C6)alkyl or a hydroxyl protecting group, n is 6, and L" is (C2-C12)alkyl, optionally interrupted by 1-3-O-.
28. The compound of claim 27 wherein L" is the alkyl residue of 1,.omega.-alkylene diol.
29. The compound of claim 27 wherein L" is -(CH2)3- and n is 2.
30. The compound of claim 27 wherein L is (C2-C7)acyl.
31. The compound of claim 27 where L is acetyl.
32. 1,3-bis(4-acetoxybutyroyl)propane.
33. The use of a compound of any of claims 1-32 in medical therapy.
34. The use of a compound of any of claims 1-32 to prepare a medicament to treat a condition or pathology amenable to treatment with gamma-hydroxybutyrate.
35. A method for treating a mammal afflicted with a condition or pathology amenable to treatment by gamma-hydroxybutyrate (GHB) comprising administering to said mammal an effective amount of a compound of any of claims 1-32.
36. A pharmaceutical composition comprising a compound of any of claims 1-32 in combination with a pharmaceutically acceptable carrier.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23472000P | 2000-09-22 | 2000-09-22 | |
US60/234,720 | 2000-09-22 | ||
PCT/US2001/029569 WO2002024715A2 (en) | 2000-09-22 | 2001-09-21 | Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2423358A1 true CA2423358A1 (en) | 2002-03-28 |
CA2423358C CA2423358C (en) | 2011-05-17 |
Family
ID=22882520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2423358A Expired - Fee Related CA2423358C (en) | 2000-09-22 | 2001-09-21 | Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers |
Country Status (7)
Country | Link |
---|---|
US (4) | US7015200B2 (en) |
EP (1) | EP1325014B1 (en) |
JP (2) | JP2004509900A (en) |
AU (1) | AU2001291173A1 (en) |
CA (1) | CA2423358C (en) |
ES (1) | ES2383673T3 (en) |
WO (1) | WO2002024715A2 (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE460146T1 (en) | 2000-09-15 | 2010-03-15 | Bruder Healthcare Co | WOUND AND TREATMENT COMPRESS AND DRESSING |
US10105259B2 (en) | 2000-09-15 | 2018-10-23 | Bruder Healthcare Company, Llc | Wound and therapy compress and dressing |
US9925087B2 (en) | 2000-09-15 | 2018-03-27 | Bruder Healthcare Company, Llc | Wound and therapy compress and dressing |
ES2383673T3 (en) * | 2000-09-22 | 2012-06-25 | Jpi Commercial, Llc | Gamma-hydroxybutyrate compositions containing carbohydrate carriers |
CA2510196C (en) * | 2002-12-20 | 2014-04-01 | Generipharm, Inc. | Intracutaneous injection |
KR20050098246A (en) * | 2003-01-13 | 2005-10-11 | 뉴 리버 파마슈티칼스, 인크. | Carbohydrate conjugates to prevent abuse of controlled substances |
US8133881B2 (en) | 2003-01-13 | 2012-03-13 | Shire Llc | Carbohydrate conjugates to prevent abuse of controlled substances |
KR20070100686A (en) * | 2004-09-07 | 2007-10-11 | 오르펀 메디칼, 인크. | Improved ghb compositions |
US8193211B2 (en) * | 2004-09-30 | 2012-06-05 | Supernus Pharmaceuticals, Inc. | Controlled release compositions of gamma-hydroxybutyrate |
AU2005304352A1 (en) * | 2004-11-10 | 2006-05-18 | The Trustees Of Columbia University In The City Of New York | Method for treatment of movement disorders |
US20120142618A1 (en) * | 2007-02-13 | 2012-06-07 | Btg International Limited | Ketogenic saccharides |
US8771735B2 (en) * | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
US8778398B2 (en) * | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
US8461197B2 (en) | 2009-04-23 | 2013-06-11 | Concert Pharmaceuticals, Inc. | 4-hydroxybutyric acid analogs |
US20120076865A1 (en) | 2010-03-24 | 2012-03-29 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
ES2804540T3 (en) * | 2011-02-14 | 2021-02-08 | Concert Pharmaceuticals Inc | Deuterated analogs of 4-hydroxybutyric acid |
WO2014078014A2 (en) | 2012-11-14 | 2014-05-22 | Metabolix, Inc. | Production of salts of 4-hydroxybutyrate using biobased raw materials |
US8591922B1 (en) | 2012-12-14 | 2013-11-26 | Jazz Pharmacuticals, Inc. | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
WO2014143139A1 (en) | 2013-03-15 | 2014-09-18 | Bruder Healthcare Company | Wound and therapy compress and dressing |
US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
JP6830671B6 (en) | 2015-09-23 | 2021-03-10 | エックスダブリューファルマ リミテッド | Prodrug of γ-hydroxybutyric acid (GHB), its composition and use |
US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (en) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS |
USD871598S1 (en) | 2016-11-30 | 2019-12-31 | Bruder Healthcare Company, Llc | Therapeutic eye mask |
USD844795S1 (en) | 2016-11-30 | 2019-04-02 | Bruder Healthcare Company, Llc | Therapeutic eye mask |
US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
US20200114015A1 (en) * | 2017-04-11 | 2020-04-16 | John K. Thottathil | Novel Alpha-Hydroxy Carboxylic Acid And Derivatives And Other GRAS- Based Prodrugs Of Gamma-Hydroxybutyrate (GHB) And Uses Thereof |
EP3740189A1 (en) | 2017-12-18 | 2020-11-25 | Tris Pharma, Inc. | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release |
WO2019126214A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release |
CA3085941A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
KR20210094513A (en) | 2018-11-19 | 2021-07-29 | 재즈 파마슈티칼즈 아일랜드 리미티드 | Alcohol-Resistant Drug Formulations |
CA3127871A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
JP2023508975A (en) | 2019-12-24 | 2023-03-06 | ジャズ ファーマシューティカルズ アイルランド リミテッド | Gamma-hydroxybutyrate (GHB) dosing |
TW202139986A (en) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | Methods of treating idiopathic hypersomnia |
CN116261451A (en) | 2020-07-24 | 2023-06-13 | 凯瑞康宁生物工程有限公司 | Pharmaceutical compositions and pharmacokinetics of gamma-hydroxybutyric acid derivatives |
AU2021357705A1 (en) | 2020-10-05 | 2023-05-18 | XWPharma Ltd. | Modified release compositions of a gamma-hydroxybutyric acid derivative |
US20230404950A1 (en) | 2020-10-08 | 2023-12-21 | Jazz Pharmaceuticals Ireland Limited | Sodium oxybate to treat idiopathic hypersomnia |
AU2021362222A1 (en) | 2020-10-16 | 2023-06-01 | Jazz Pharmaceuticals Ireland Limited | Treatment methods using ghb |
JP2024511991A (en) | 2021-03-19 | 2024-03-18 | エックスダブリューファーマ リミテッド | Pharmacokinetics of combined release formulations of gamma-hydroxybutyric acid derivatives |
WO2023062018A1 (en) | 2021-10-11 | 2023-04-20 | Jazz Pharmaceuticals Ireland Limited | Method of administering oxybate |
WO2023135150A1 (en) | 2022-01-11 | 2023-07-20 | Jazz Pharmaceuticals Ireland Limited | Method of administering oxybate |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2226398A1 (en) * | 1972-05-31 | 1973-12-13 | Boehringer Sohn Ingelheim | NEW HEART GLYCOSIDES AND METHODS FOR THEIR PRODUCTION |
DE2702687A1 (en) * | 1977-01-24 | 1978-07-27 | Boehringer Sohn Ingelheim | 3'-Acyl-altromethylosyl-bufatrienolide derivs. - used as orally resorbable cardiotonic agents |
JPS60168044A (en) * | 1984-02-10 | 1985-08-31 | Sharp Corp | Moisture sensitive material |
US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
GB8508508D0 (en) * | 1985-04-01 | 1985-05-09 | Creighton A M | Pharmaceutical compositions |
US4738985A (en) * | 1986-03-19 | 1988-04-19 | The University Of Toronto Innovations Foundations | Pharmaceutical composition and treatment |
IT1238344B (en) * | 1989-10-20 | 1993-07-13 | Sigma Tau Ind Farmaceuti | ESTERS OF L-CARNITINE WITH GAMMA-HYDROXYBUTIRRIC ACID AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT FOR THE INHIBITION OF NEURONAL DEGENERATION AND IN THE TREATMENT OF COMA |
IT1240760B (en) * | 1990-02-12 | 1993-12-17 | Sigma Tau Ind Farmaceuti | ACYL-L-CARNITINE ESTERS WITH GAMMA-HYDROXYBUTIRRIC ACID AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM FOR THE INHIBITION OF NEURONAL DEGENERATION AND IN THE TREATMENT OF COMA. |
DE4026265A1 (en) | 1990-08-20 | 1992-02-27 | Boehringer Mannheim Gmbh | NEW PHOSPHOLIPID DERIVATIVES OF NUCLEOSIDES, THEIR PRODUCTION AND THEIR USE AS ANTIVIRAL MEDICINAL PRODUCTS |
DE4113984C2 (en) * | 1991-04-29 | 2002-05-08 | Koehler Chemie Dr Franz | Salts of 4-hydroxy butyric acid |
GB9112212D0 (en) | 1991-06-06 | 1991-07-24 | Gregoriadis Gregory | Pharmaceutical compositions |
IT1261485B (en) | 1993-06-24 | 1996-05-23 | Sigma Tau Ind Farmaceuti | USE OF ACIL L-CARNITINE RANGE-HYDROXYBUTIRRATE FOR THE TREATMENT OF DRUG ADDICTION. |
JP2746079B2 (en) * | 1993-09-07 | 1998-04-28 | 正和薬品株式会社 | Blood glucose elevation inhibitor and lipid metabolism improver |
SE502990C2 (en) | 1993-11-22 | 1996-03-04 | Perstorp Ab | Use of an inositol trisphosphate ester for the preparation of an analgesic drug |
SE503122C2 (en) * | 1993-11-22 | 1996-03-25 | Perstorp Ab | Use of an inositol trisphosphate ester for the treatment of inflammatory conditions |
SE502989C2 (en) * | 1993-11-22 | 1996-03-04 | Perstorp Ab | Use of an inositol trisphosphate ester for drug preparation |
DK2283834T3 (en) * | 1997-03-17 | 2016-08-15 | Btg Int Ltd | Therapeutic compositions comprising ketone compounds and precursors thereof |
US5990162A (en) | 1997-08-29 | 1999-11-23 | Orphan Medical, Inc. | Method for treatment of fibromyalgia and chronic fatigue syndrome |
US6623730B1 (en) * | 1999-09-14 | 2003-09-23 | Tepha, Inc. | Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
ES2383673T3 (en) * | 2000-09-22 | 2012-06-25 | Jpi Commercial, Llc | Gamma-hydroxybutyrate compositions containing carbohydrate carriers |
US7686215B2 (en) | 2005-05-21 | 2010-03-30 | Apple Inc. | Techniques and systems for supporting podcasting |
US9405855B2 (en) | 2014-03-27 | 2016-08-02 | Sap Ag | Processing diff-queries on property graphs |
-
2001
- 2001-09-21 ES ES01971269T patent/ES2383673T3/en not_active Expired - Lifetime
- 2001-09-21 WO PCT/US2001/029569 patent/WO2002024715A2/en active Application Filing
- 2001-09-21 US US10/381,224 patent/US7015200B2/en not_active Expired - Lifetime
- 2001-09-21 JP JP2002529123A patent/JP2004509900A/en active Pending
- 2001-09-21 EP EP01971269A patent/EP1325014B1/en not_active Expired - Lifetime
- 2001-09-21 CA CA2423358A patent/CA2423358C/en not_active Expired - Fee Related
- 2001-09-21 AU AU2001291173A patent/AU2001291173A1/en not_active Abandoned
-
2005
- 2005-07-18 US US11/183,482 patent/US7572605B2/en not_active Expired - Lifetime
-
2009
- 2009-05-13 US US12/465,069 patent/US8778301B2/en not_active Expired - Fee Related
-
2012
- 2012-09-06 JP JP2012196299A patent/JP2012246312A/en active Pending
-
2013
- 2013-05-20 US US13/897,748 patent/US20130324759A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090215890A1 (en) | 2009-08-27 |
US20100022643A2 (en) | 2010-01-28 |
WO2002024715A3 (en) | 2003-05-08 |
US7015200B2 (en) | 2006-03-21 |
WO2002024715A2 (en) | 2002-03-28 |
EP1325014B1 (en) | 2012-05-23 |
JP2012246312A (en) | 2012-12-13 |
EP1325014A2 (en) | 2003-07-09 |
US20130324759A1 (en) | 2013-12-05 |
US20050250848A1 (en) | 2005-11-10 |
US20040092455A1 (en) | 2004-05-13 |
US8778301B2 (en) | 2014-07-15 |
CA2423358C (en) | 2011-05-17 |
ES2383673T3 (en) | 2012-06-25 |
JP2004509900A (en) | 2004-04-02 |
US7572605B2 (en) | 2009-08-11 |
AU2001291173A1 (en) | 2002-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2423358A1 (en) | Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers | |
US8071535B2 (en) | Guanidinium derivatives for improved cellular transport | |
US20120004309A1 (en) | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | |
JP2004509900A5 (en) | ||
RU2006146042A (en) | DIAMINE AGONISTS OF 2-ADRENERGIC RECEPTORS | |
MX9303598A (en) | TAXOL POLYMER CONJUGATES, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
US20090175792A1 (en) | Glycomimetic inhibitors of siglec-8 | |
WO2008010463A1 (en) | Polymer conjugate of combretastatin | |
JP6862428B6 (en) | Aminoglycoside derivatives and their use in the treatment of hereditary diseases | |
RU2003134629A (en) | CEPHEMA COMPOUNDS | |
CA2141679C (en) | New derivatives of neuraminic acid | |
US5350841A (en) | Ganglioside derivatives | |
KR890006228A (en) | Polyamine Derivatives as Antitumor Agents | |
CN101580530A (en) | Amino acid conjugate prodrug of pentacyclic triterpenoid and medical application thereof | |
JP7346571B2 (en) | Sugar-conjugated L-DOPA and/or DOPA decarboxylase inhibitors for the treatment of dopamine-responsive disorders | |
TWI820068B (en) | Method for improving the oral bioavailability of a drug | |
JP5327839B2 (en) | Method for producing sialic acid derivative and its use as an influenza virus inhibitor | |
HUT70509A (en) | Anthracycline conjugates, process for their preparation and pharmaceutical compositions contg. them | |
JPS62135490A (en) | Steroidal glycolipid as host resistance promoter | |
KR20040051958A (en) | Sphingolipid derivatives modified by polyethylene glycol and composition containing the same | |
ES2380864B1 (en) | INHIBITORS OF THE DIVISION OF TUMOR CELLS. | |
WO2018167775A1 (en) | Codrugs of disaccharides and branched-chain amino acids and uses thereof | |
Fung et al. | Pharmacokinetics and drug design | |
Miklán et al. | Cell-penetrating and targeting peptide conjugates of antitumor drugs: Synthesis, chemical and in vitro biological characterization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20150921 |